Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0081348
DC Field | Value | |
---|---|---|
dc.title | Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma | |
dc.contributor.author | Kanojia D. | |
dc.contributor.author | Garg M. | |
dc.contributor.author | Saini S. | |
dc.contributor.author | Agarwal S. | |
dc.contributor.author | Parashar D. | |
dc.contributor.author | Jagadish N. | |
dc.contributor.author | Seth A. | |
dc.contributor.author | Bhatnagar A. | |
dc.contributor.author | Gupta A. | |
dc.contributor.author | Kumar R. | |
dc.contributor.author | Lohiya N.K. | |
dc.contributor.author | Suri A. | |
dc.date.accessioned | 2019-11-05T02:07:37Z | |
dc.date.available | 2019-11-05T02:07:37Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Kanojia D., Garg M., Saini S., Agarwal S., Parashar D., Jagadish N., Seth A., Bhatnagar A., Gupta A., Kumar R., Lohiya N.K., Suri A. (2013). Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. PLoS ONE 8 (12) : e81348. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0081348 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/161446 | |
dc.description.abstract | Background: Majority of bladder cancer deaths are caused due to transitional cell carcinoma (TCC) which is the most prevalent and chemoresistant malignancy of urinary bladder. Therefore, we analyzed the role of Sperm associated antigen 9 (SPAG9) in bladder TCC. Methodology and Findings: We examined SPAG9 expression and humoral response in 125 bladder TCC patients. Four bladder cancer cell lines were assessed for SPAG9 expression. In addition, we investigated the effect of SPAG9 ablation on cellular proliferation, cell cycle, migration and invasion in UM-UC-3 bladder cancer cells by employing gene silencing approach. Our SPAG9 gene and protein expression analysis revealed SPAG9 expression in 81% of bladder TCC tissue specimens. High SPAG9 expression (>60% SPAG9 positive cells) was found to be significantly associated with superficial non-muscle invasive stage (P = 0.042) and low grade tumors (P = 0.002) suggesting SPAG9 putative role in early spread and tumorigenesis. Humoral response against SPAG9 was observed in 95% of patients found positive for SPAG9 expression. All four bladder cancer cell lines revealed SPAG9 expression. In addition, SPAG9 gene silencing in UM-UC-3 cells resulted in induction of G 0 -G 1 arrest characterized by up-regulation of p16 and p21 and consequent down-regulation of cyclin E, cyclin D and cyclin B, CDK4 and CDK1. Further, SPAG9 gene silencing also resulted in reduction in cellular growth, and migration and invasion ability of cancer cells in vitro. Conclusions: Collectively, our data in clinical specimens indicated that SPAG9 is potential biomarker and therapeutic target for bladder TCC. © 2013 Kanojia et al. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20191101 | |
dc.subject | cancer testis antigen | |
dc.subject | cyclin B | |
dc.subject | cyclin D | |
dc.subject | cyclin dependent kinase 1 | |
dc.subject | cyclin dependent kinase 4 | |
dc.subject | cyclin E | |
dc.subject | protein p16 | |
dc.subject | protein p21 | |
dc.subject | sperm associated antigen 9 | |
dc.subject | unclassified drug | |
dc.subject | adult | |
dc.subject | antigen expression | |
dc.subject | article | |
dc.subject | cancer cell | |
dc.subject | cancer grading | |
dc.subject | cell cycle arrest | |
dc.subject | cell cycle G0 phase | |
dc.subject | cell cycle G1 phase | |
dc.subject | cell invasion | |
dc.subject | cell migration | |
dc.subject | cell proliferation | |
dc.subject | controlled study | |
dc.subject | down regulation | |
dc.subject | female | |
dc.subject | gene expression regulation | |
dc.subject | gene silencing | |
dc.subject | genetic association | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | human tissue | |
dc.subject | humoral immunity | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | middle aged | |
dc.subject | non muscle invasive bladder cancer | |
dc.subject | transitional cell carcinoma | |
dc.subject | upregulation | |
dc.subject | Adaptor Proteins, Signal Transducing | |
dc.subject | Adult | |
dc.subject | Carcinoma, Transitional Cell | |
dc.subject | Cell Cycle | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Proliferation | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Tumor Markers, Biological | |
dc.subject | Urinary Bladder Neoplasms | |
dc.type | Article | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.description.doi | 10.1371/journal.pone.0081348 | |
dc.description.sourcetitle | PLoS ONE | |
dc.description.volume | 8 | |
dc.description.issue | 12 | |
dc.description.page | e81348 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1371_journal_pone_0081348.pdf | 24.11 MB | Adobe PDF | OPEN | Published | View/Download |
This item is licensed under a Creative Commons License